Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Exelixis Inc (NASDAQ:EXEL)

7.69
Delayed Data
As of Jun 24
 -0.16 / -2.04%
Today’s Change
3.31
Today|||52-Week Range
7.88
+36.35%
Year-to-Date
5 Reasons to Hate Biotech Stocks
Jun 23 / MotleyFool.com - Paid Partner Content
4 Cancer Drug Developers You Need to Have on Your Radar This Year
Jun 15 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close7.85
Today’s open7.33
Day’s range7.20 - 7.86
Volume11,569,801
Average volume (3 months)5,208,649
Market cap$1.8B
Dividend yield--
Data as of 4:00pm ET, 06/24/2016

Growth & Valuation

Earnings growth (last year)+41.30%
Earnings growth (this year)-20.37%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+48.03%
P/E ratioNM
Price/Sales31.75
Price/Book--

Competitors

 Today’s
change
Today’s
% change
NKTRNektar Therapeutics-1.16-7.46%
ABCOAdvisory Board Co-0.76-2.13%
INCRINC Research Holding...-0.85-2.16%
LXRXLexicon Pharmaceutic...-0.28-2.01%
Data as of 4:00pm ET, 06/24/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)-$0.28
Annual revenue (last year)$37.2M
Annual profit (last year)-$169.7M
Net profit margin-456.63%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Michael M. Morrissey
Chief Financial Officer &
Executive Vice President
Christopher J. Senner
Corporate headquarters
South San Francisco, California

Forecasts

Partner Offers

Search for Jobs